Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets ...

A team of international scientists has developed a method to predict the risk of developing cancer from a blood disorder common in older adults, according to a study published in the journal Blood.

FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set ...

Biotech company CERo Therapeutics Holdings, Inc. (CERO) on Wednesday announced an agreement with the University of California ...

Hepatic Artery Infusion (HAI) therapy uses a pump that is implanted just below the skin in a patient's abdominal wall to deliver medicine directly to the liver through the hepatic ...

CERo Therapeutics Holdings, Inc., (NASDAQ: CERO) shares were unchanged Wednesday. The company, an innovative immunotherapy company seeking to advance the next generation of engineered T cell ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced its 2024 ...

StockNews.com lowered shares of Kura Oncology (NASDAQ:KURA – Free Report) from a buy rating to a hold rating in a research ...

When 10-year-old Evie King was diagnosed with Acute Myeloid Leukemia (AML) it came as a shock to her family and upended their ...

Taste Buds A new online column by Vivanda Felice and Pipa Benoit, pseudonyms for two Monroe County foodies dedicated to ...

Rodabe N. Amaria, MD, explains a trial of OBX-115, a novel engineered tumor infiltrating lymphocyte therapy, in checkpoint ...